Mirati Therapeutics, Inc.·4

Feb 19, 7:00 PM ET

LEMASTERS CHRISTOPHER C. 4

4 · Mirati Therapeutics, Inc. · Filed Feb 19, 2019

Insider Transaction Report

Form 4
Period: 2019-02-14
LEMASTERS CHRISTOPHER C.
EVP, Chief Business Officer
Transactions
  • Sale

    Common Stock

    2019-02-14$72.06/sh18,562$1,337,4890 total
  • Sale

    Common Stock

    2019-02-14$71.65/sh41,438$2,968,96618,562 total
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2019-02-1460,00060,000 total
    Exercise: $6.45Exp: 2026-10-02Common Stock (60,000 underlying)
  • Exercise/Conversion

    Common Stock

    2019-02-14$6.45/sh+60,000$387,00060,000 total
Footnotes (4)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2018.
  • [F2]This transaction was executed in multiple trades at prices ranging from $71.03 to $72.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $72.03 to $72.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.

Documents

1 file
  • 4
    marketforms-44141.xmlPrimary

    PRIMARY DOCUMENT